{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:28:14Z","timestamp":1790616494264,"version":"4.1.0"},"reference-count":10,"publisher":"Bioscientifica","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["edm.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"\n Summary<\/jats:title>\n We used the sodium-glucose cotransporter 2 inhibitor, luseogliflozin in two patients with diabetes mellitus with Child\u2013Pugh classification B cirrhosis and cirrhotic ascites. In each case, luseogliflozin was safely used for over three years and was also considered effective in reducing ascites. In one of the patients in particular, when luseogliflozin was discontinued and switched to insulin treatment before colorectal cancer surgery, ascites accumulation was observed within two weeks, which subsequently decreased rapidly when luseogliflozin was restarted. In this case, the effect of luseogliflozin on ascites was evident by the clear increase and decrease in ascites over a short period of time, as evaluated using body weight, abdominal circumference and CT scan, without changing her other diuretic medication. Although sodium-glucose cotransporter 2 inhibitors need to be used with caution, they might be an option for the treatment of diabetes in patients with cirrhosis.<\/jats:p>\n <\/jats:sec>\n \n Learning points<\/jats:title>\n \n \n Luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, is effective for glycemic control and safe in patients with cirrhosis.<\/jats:p>\n <\/jats:list-item>\n \n Luseogliflozin administration reduced ascites in patients with diabetes mellitus.<\/jats:p>\n <\/jats:list-item>\n \n Caution is warranted, as discontinuation of sodium-glucose cotransporter 2 inhibitors might lead to an increase in ascites.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:sec>","DOI":"10.1530\/edm-25-0015","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T11:30:29Z","timestamp":1753356629000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-2","source":"Crossref","is-referenced-by-count":1,"title":["SGLT2 inhibitor administration to two patients with diabetes mellitus with ascites due to cirrhosis"],"prefix":"10.1530","volume":"2025","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7914-1927","authenticated-orcid":true,"given":"Koji","family":"Nagayama","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Diabetes, and Metabolism, Hamamatsu Medical Center, Hamamatsu, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risako","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes, and Metabolism, Hamamatsu Medical Center, Hamamatsu, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ajima","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes, and Metabolism, Hamamatsu Medical Center, Hamamatsu, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakurako","family":"Orikasa","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes, and Metabolism, Hamamatsu Medical Center, Hamamatsu, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misaki","family":"Aoshima","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes, and Metabolism, Hamamatsu Medical Center, Hamamatsu, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Oki","sequence":"additional","affiliation":[{"name":"Center of Diabetes and Endocrinology, Hamamatsu-Kita Hospital, Hamamatsu, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"World J Gastroenterol","first-page":"2506","article-title":"Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease","volume":"15","author":"Donadon V","year":"2009","unstructured":"Donadon V\n, \nBalbi M\n, \nGhersetti M\n, et al.\n Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol 2009 15 2506\u20132511. (https:\/\/doi.org\/10.3748\/wjg.15.2506)"},{"key":"bib2","series-title":"Clin Gastroenterol Hepatol","first-page":"2148","article-title":"Effects of metformin exposure on survival in a large national cohort of patients with diabetes and cirrhosis","volume":"19","author":"Kaplan DE","year":"2021","unstructured":"Kaplan DE\n, \nSerper M\n, \nJohn BV\n, et al.\n Effects of metformin exposure on survival in a large national cohort of patients with diabetes and cirrhosis. Clin Gastroenterol Hepatol 2021 19 2148\u20132160. (https:\/\/doi.org\/10.1016\/j.cgh.2020.08.026)"},{"key":"bib3","series-title":"Annu Rev Physiol","first-page":"503","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function","volume":"83","author":"Vallon V","year":"2021","unstructured":"Vallon V\n & \nVerma S\n\n. Effects of SGLT2 inhibitors on kidney and cardiovascular function. Annu Rev Physiol 2021 83 503\u2013528. (https:\/\/doi.org\/10.1146\/annurev-physiol-031620-095920)"},{"key":"bib4","series-title":"Clin Pharmacol Drug Development","first-page":"439","article-title":"Luseogliflozin, an SGLT2 inhibitor, in Japanese patients with mild\/moderate hepatic impairment: a pharmacokinetic study","volume":"6","author":"Samukawa Y","year":"2017","unstructured":"Samukawa Y\n, \nSata M\n, \nFurihata K\n, et al.\n Luseogliflozin, an SGLT2 inhibitor, in Japanese patients with mild\/moderate hepatic impairment: a pharmacokinetic study. Clin Pharmacol Drug Development 2017 6 439\u2013447. (https:\/\/doi.org\/10.1002\/cpdd.364)"},{"key":"bib5","series-title":"Hepatology","first-page":"1880","article-title":"Sodium-glucose cotransporter 2 inhibitors ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes","volume":"72","author":"Montalvo-Gordon I","year":"2020","unstructured":"Montalvo-Gordon I\n, \nChi-Cervera LA\n & \nGarc\u00eda-Tsao G\n\n. Sodium-glucose cotransporter 2 inhibitors ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes. Hepatology 2020 72 1880\u20131882. (https:\/\/doi.org\/10.1002\/hep.31270)"},{"key":"bib6","series-title":"Am J Gastroenterol","first-page":"618","article-title":"Empagliflozin eliminates refractory ascites and hepatic hydrothorax in a patient with primary biliary cirrhosis","volume":"116","author":"Kalambokis GN","year":"2021","unstructured":"Kalambokis GN\n, \nTsiakas I\n, \nFilippas-Ntekuan S\n, et al.\n Empagliflozin eliminates refractory ascites and hepatic hydrothorax in a patient with primary biliary cirrhosis. Am J Gastroenterol 2021 116 618\u2013619. (https:\/\/doi.org\/10.14309\/ajg.0000000000000995)"},{"key":"bib7","series-title":"J Clin Med","first-page":"2253","article-title":"The effects of SGLT2 inhibitors on liver cirrhosis patients with refractory ascites: a literature review","volume":"12","author":"Miyamoto Y","year":"2023","unstructured":"Miyamoto Y\n, \nHonda A\n, \nYokose S\n, et al.\n The effects of SGLT2 inhibitors on liver cirrhosis patients with refractory ascites: a literature review. J Clin Med 2023 12 2253. (https:\/\/doi.org\/10.3390\/jcm12062253)"},{"key":"bib8","series-title":"Diabetes Diabetes Ther","first-page":"953","article-title":"Practical approach to initiating SGLT2 inhibitors in type 2","volume":"8","author":"Gomez-Peralta F","year":"2017","unstructured":"Gomez-Peralta F\n, \nAbreu C\n, \nLecube A\n, et al.\n Practical approach to initiating SGLT2 inhibitors in type 2. Diabetes Diabetes Ther 2017 8 953\u2013962. (https:\/\/doi.org\/10.1007\/s13300-017-0277-0)"},{"key":"bib9","series-title":"Diabetes Res Clin Pract","article-title":"Effect of sodium-glucose co-transporter 2 inhibitors on plasma potassium: a meta-analysis","volume":"196","author":"Charlwood C","year":"2023","unstructured":"Charlwood C\n, \nChudasama J\n, \nDarling AL\n, et al.\n Effect of sodium-glucose co-transporter 2 inhibitors on plasma potassium: a meta-analysis. Diabetes Res Clin Pract 2023 196 110239. (https:\/\/doi.org\/10.1016\/j.diabres.2023.110239)"},{"key":"bib10","series-title":"Diabetes Obes Metabol","first-page":"2402","article-title":"Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin","volume":"23","author":"Saffo S","year":"2021","unstructured":"Saffo S\n, \nKaplan DE\n, \nMahmud N\n, et al.\n Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin. Diabetes Obes Metabol 2021 23 2402\u20132408. (https:\/\/doi.org\/10.1111\/dom.14488)"}],"container-title":["Endocrinology, Diabetes & Metabolism Case Reports"],"original-title":[],"link":[{"URL":"https:\/\/edm.bioscientifica.com\/view\/journals\/edm\/2025\/3\/EDM-25-0015.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/edm.bioscientifica.com\/downloadpdf\/journals\/edm\/2025\/3\/EDM-25-0015.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/edm.bioscientifica.com\/downloadpdf\/journals\/edm\/2025\/3\/EDM-25-0015.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:48:35Z","timestamp":1784555315000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/edm\/article\/3873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":10,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.1530\/edm-25-0015","relation":{},"ISSN":["2052-0573"],"issn-type":[{"value":"2052-0573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}